Chimeric antigen receptor specific for tumor cells
The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.
1. A chimeric antigen receptor (CAR), comprising an antigen binding domain specific for CLA in combination with one or more antigen binding domains specific for an antigen selected from the group consisting of CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8.
2. The chimeric antigen receptor (CAR) according to claim 1 , wherein the one or more antigen binding domains comprise at least two different antigen binding domains specific for at least two different antigens selected from the group consisting of CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8.
3. The chimeric antigen receptor (CAR) according to claim 1 , wherein the one or more antigen binding domains comprise at least two different antigen binding domains specific for at least two different antigens selected from the group consisting of CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8, wherein the at least two antigen binding domains are conjugated to the same or different transmembrane domain and/or intracellular signaling domain.
4. The chimeric antigen receptor (CAR) according to claim 1 , wherein the chimeric antigen receptor comprises a 4-1BB, CD8 or CD28 transmembrane domain and one or more of CD28, CD137 and CD3zeta intracellular signaling domain.